Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2021-03-22 Board/Management Inform…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Förändringar i Medivirs ledning och styrelse
Board/Management Information Classification · 99% confidence The document text is a formal announcement from Medivir AB regarding significant changes in its senior management and board of directors. Key phrases include 'Förändringar i Medivirs ledning och styrelse' (Changes in Medivir's management and board), the resignation of the CEO ('lämnar vd-posten'), proposals for a new Chairman of the Board, and details about director re-elections and departures. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2021-03-22 Swedish
Changes in Medivir’s management and Board of Directors
Board/Management Information Classification · 99% confidence The document explicitly announces changes in the company's management (CEO resignation) and Board of Directors (proposals for new Chairman and Board Members). This content directly aligns with the definition of 'Board/Management Information'. The document title is 'Changes in Medivir's management and Board of Directors'. This clearly points to the MANG code.
2021-03-22 English
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding ('Holder: Bengt Julander') for Medivir Aktiebolag, specifically noting the 'Reason for major shareholding notification Buy' and providing 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights (10.47834 %). This structure—reporting changes in ownership that cross a threshold—is characteristic of a Major Shareholding Notification. This aligns directly with the definition for 'Major Shareholding Notification' (Code: MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a director's dealing report (DIRS), but specifically tracks significant ownership changes.
2021-03-18 English
Resolution at the extraordinary general meeting in Medivir on 11 March 2021
Share Issue/Capital Change Classification · 99% confidence The document explicitly details a resolution passed at an 'extraordinary general meeting' concerning a 'directed issue of shares' to raise capital (SEK 27,828,000) via the issuance of new class B shares to a specific entity (LINC AB). This action directly relates to changing the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it references a general meeting, the core subject is the capital raise, not the voting results (DVA) or the general meeting presentation (AGM-R). The document length is moderate, but the content is a definitive announcement of a capital event.
2021-03-11 English
Beslut vid extra bolagsstämma i Medivir den 11 mars 2021
Share Issue/Capital Change Classification · 99% confidence The document is titled 'Beslut vid extra bolagsstämma' (Decision at the Extraordinary General Meeting) and details a specific resolution passed: a directed new share issue ('Riktad nyemission av aktier') to raise capital. This action directly relates to changes in the company's capital structure and fundraising activities. While it originates from a shareholder meeting, the core subject is the capital raise, making 'Capital/Financing Update' (CAP) the most appropriate classification over 'AGM-R' (which is for presentations/materials) or 'SHA' (which is for general share issues/splits, whereas this is a specific financing event). Given the explicit mention of raising capital through a directed share issue, CAP is the best fit.
2021-03-11 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Medivir AB covering the period January to December 2020. It contains comprehensive financial summaries (net sales, EBITDA, earnings per share, cash flow, and liquidity) for both the quarter and the full year, alongside detailed management commentary, project updates, and operational highlights. As it provides substantive financial statements and analysis for a period shorter than a full fiscal year (or in this case, the final quarterly/annual summary before the full audited annual report), it fits the definition of an Interim/Quarterly Report (IR). FY 2020
2021-02-26 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.